Buy Biocryst
Amount
Latest price
$11.07
(£1.00 = $1.329)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$1.868B
P/E ratio
-34.59
EPS
-$0.258
Beta
1.05
Dividend rate
N/A
Dividend yield
N/A
About
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
CEO
Mr. Jon P. Stonehouse
Employees
580
Sector
Health
Company HQ
DURHAM, United States of America
Website
News
BioCryst: Strong Opportunity For A Double With A Proven Therapy
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy reliance on ORLADEYO, BCRX stock remains a "Buy" due to its strong market presence and growth potential in the hereditary angioedema therapy market. The 10-K report highlights competition, including late-stage therapies and an upcoming PDUFA date for KalVista's sebetralstat, which could impact market dynamics.
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Steven Seedhouse - Cantor Maury Raycroft - Jefferies Jessica Fye - JP Morgan Stacy Ku - TD Cowen Gena Wang - Barclays Laura Chico - Wedbush Securities Liisa Bayko - Evercore ISI Serge Belanger - Needham & Co. Jonathan Wolleben - Citizens JMP Operator Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.